Zscaler R&D increased by 14.3% to $229.14M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 34.1%, from $170.86M to $229.14M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 40.1% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $40.95M | $56.18M | $65.22M | $69.20M | $76.58M | $78.15M | $74.95M | $85.77M | $92.64M | $97.44M | $113.54M | $122.18M | $124.96M | $139.15M | $154.25M | $170.86M | $169.77M | $177.61M | $200.50M | $229.14M |
| QoQ Change | — | +37.2% | +16.1% | +6.1% | +10.7% | +2.1% | -4.1% | +14.4% | +8.0% | +5.2% | +16.5% | +7.6% | +2.3% | +11.4% | +10.9% | +10.8% | -0.6% | +4.6% | +12.9% | +14.3% |
| YoY Change | — | — | — | — | +87.0% | +39.1% | +14.9% | +23.9% | +21.0% | +24.7% | +51.5% | +42.5% | +34.9% | +42.8% | +35.9% | +39.8% | +35.9% | +27.6% | +30.0% | +34.1% |